Results 141 to 150 of about 25,234 (166)

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Nature Reviews Cancer, 2019
Jonathan J Havel, Diego Chowell, Timothy A Chan   +2 more
exaly  

SGLT2-Inhibitor für Postinfarktpatienten?

CardioVasc, 2023
openaire   +1 more source

Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial

Lancet, The, 2007
Vivian Wing Yan Lee, Wai Keung Leung, James Yun Wong Lau   +2 more
exaly  

Evaluating an RSV inhibitor

Nature Reviews Microbiology, 2022
exaly  

Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis

Lancet, The, 2020
Mauro Chiarito, Francesco Cannata, Davide Cao   +2 more
exaly  

SGLT2 Inhibitors and Iron

JACC: Heart Failure, 2023
openaire   +1 more source

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality

Cancer Cell, 2018
Ewa Gogola, Wouter W Wiegant, Daniel J Vis   +2 more
exaly  

UHCW audit on SGLT2 inhibitor (SGLT2-i) use

Endocrine Abstracts, 2017
Maria Mytilinaiou, Georgios K Dimitriadis, Allan Davasgaium, Diane Sambrook, Claire Hewins, Nilisha Nalawade, Dimitris K Grammatopoulos, Harpal S Randeva   +7 more
openaire   +1 more source

SGLT2 inhibitors and cardiovascular outcomes

Drug and Therapeutics Bulletin, 2017
openaire   +2 more sources

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

Lancet, The, 2010
Uri Lopatin, Patrick F Smith
exaly